Announcement on the Estimated Guarantee Quota for a Subsidiary
Securities Code: 002422 Securities Abbreviation: Kelun Pharmaceutical Announcement No.: 2026-024
Sichuan Kelun Pharmaceutical Co., Ltd.
Announcement on the Estimated Guarantee Quota for a Subsidiary
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or material omissions.
I. Overview of Guarantee Situation
Sichuan Kelun Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company" or "Kelun Pharmaceutical") plans to provide a guarantee quota of up to RMB 1 billion for its subsidiary, Yili Channing Biotechnology Co., Ltd. (hereinafter referred to as "Channing Biotechnology"), to obtain financing from banks and other financial institutions. It is proposed that the shareholders' meeting authorize the Chairman or General Manager to sign the aforementioned guarantee agreements and other relevant legal documents for Channing Biotechnology. The authorization period shall be one year from the date of approval by the Company's shareholders' meeting.
On April 1, 2026, the Company held the twelfth meeting of the Eighth Board of Directors. The proposal "Regarding the Estimated Guarantee Quota for a Subsidiary" was deliberated and approved by 9 votes in favor, 0 votes against, and 0 abstentions. This matter still needs to be submitted to the Company's shareholders' meeting for deliberation and does not require approval from relevant departments. The Company will not convene separate board or shareholder meetings for guarantee matters within the aforementioned quota scope, nor will it form separate board or shareholder resolutions for each guarantee.